Overall Gadolinium Exposure Within the First 5 Months After Injection of Human Equivalent Doses of Gadopiclenol, Gadoterate, or Gadobutrol in Healthy Rats Article Swipe
Marlène Rasschaert
,
Emilie Couloumy
,
Elisabeth Renard
,
Claire Hollenbeck
,
Nathalie Fretellier
,
Izabela Strzeminska
,
Ilona Janot
,
Margeaux Lefebvre
,
Nathalie Decout
,
Cécile Factor
,
Philippe Robert
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1097/rli.0000000000001194
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1097/rli.0000000000001194
Introduction: Gadopiclenol is a high relaxivity macrocyclic and nonionic Gadolinium-Based Contrast Agent (GBCA) for central nervous system (CNS) and Body MRI, approved in September 2022 by the Food and Drug Administration and in December 2023 by the European Medicine Agency and others European health authorities. Gadopiclenol is currently indicated at half gadolinium-dose (0.05 mmol/kg body weight) compared to the other nonspecific marketed GBCAs. This study aims to evaluate the impact of this gadolinium (Gd) dose reduction in terms of overall Gd body exposure. Requiring tissue samples at different times, this information is only accessible through animal experiment. In this study, the Gd exposure over a 5-month period was evaluated in healthy rats after a single injection of gadopiclenol in comparison with 2 other macrocyclic GBCAs approved for human use, gadobutrol and gadoterate, all administered at their respective human equivalent dose (HED). Material and Methods: Healthy 9-week-old female Sprague-Dawley rats were randomly allocated to 4 groups, receiving 1 single intravenous injection of gadoterate (Dotarem, 0.6 mmol/kg), gadobutrol (Gadovist, 0.6 mmol/kg), gadopiclenol (Elucirem, 0.3 mmol/kg), or saline (control group). Animals were euthanized 1 day (D1), 1 week (W1), 1 month (M1), or 5 months (M5) after the injection (n = 10/group and time-point). Selected tissues (including central [CNS] and peripheric nervous system [PNS] organs, excretion organs, bone) were collected for subsequent total Gd determination with inductively coupled plasma mass spectrometry. Based on Gd concentration measurements at these different time points, the 5 months overall exposure to Gd in each organ was estimated by calculating the area under the curve (AUC), between the first and the last time point. The whole study was performed in a blinded manner. Results: Following gadopiclenol administration to rats at the HED, overall Gd exposure over 5 months was found to be 25% to 40% lower compared to gadoterate and gadobutrol, respectively. Organ by organ, Gd exposure reduction is observed over the studied period in the plasma, CNS (cerebellum, cortical brain, subcortical brain, brain stem, spinal cord), PNS (spinal nodes, sciatic nerve, footpads), the spleen, the skin, the liver, and the kidney. In the femur, the Gd exposure after gadopiclenol administration was higher or equivalent compared to gadobutrol and gadoterate in the mineral parts of the bone (diaphysis and epiphysis), but lower in the bone marrow. Residual Gd found in each tissue studied is extremely low relative to the injected dose), with values ranging from 10 −6 (CNS) to 10 −3 (kidney, mineral bone) % injected dose/g of organ. Conclusions: Under our experimental conditions, the overall measured Gd exposure over 5 months following gadopiclenol injection in rats at the HED is 25–40% lower than that after gadoterate and gadobutrol injections, respectively.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1097/rli.0000000000001194
- OA Status
- hybrid
- References
- 50
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4410506307
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4410506307Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1097/rli.0000000000001194Digital Object Identifier
- Title
-
Overall Gadolinium Exposure Within the First 5 Months After Injection of Human Equivalent Doses of Gadopiclenol, Gadoterate, or Gadobutrol in Healthy RatsWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-05-19Full publication date if available
- Authors
-
Marlène Rasschaert, Emilie Couloumy, Elisabeth Renard, Claire Hollenbeck, Nathalie Fretellier, Izabela Strzeminska, Ilona Janot, Margeaux Lefebvre, Nathalie Decout, Cécile Factor, Philippe RobertList of authors in order
- Landing page
-
https://doi.org/10.1097/rli.0000000000001194Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1097/rli.0000000000001194Direct OA link when available
- Concepts
-
Gadobutrol, Gadolinium, Medicine, Nuclear medicine, Body weight, Magnetic resonance imaging, Internal medicine, Chemistry, Radiology, Organic chemistryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
50Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4410506307 |
|---|---|
| doi | https://doi.org/10.1097/rli.0000000000001194 |
| ids.doi | https://doi.org/10.1097/rli.0000000000001194 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40384088 |
| ids.openalex | https://openalex.org/W4410506307 |
| fwci | 0.0 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000818 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Animals |
| mesh[1].qualifier_ui | Q000493 |
| mesh[1].descriptor_ui | D003287 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | pharmacokinetics |
| mesh[1].descriptor_name | Contrast Media |
| mesh[2].qualifier_ui | Q000008 |
| mesh[2].descriptor_ui | D003287 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | administration & dosage |
| mesh[2].descriptor_name | Contrast Media |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D051381 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Rats |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D005260 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Female |
| mesh[5].qualifier_ui | Q000493 |
| mesh[5].descriptor_ui | D009942 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | pharmacokinetics |
| mesh[5].descriptor_name | Organometallic Compounds |
| mesh[6].qualifier_ui | Q000008 |
| mesh[6].descriptor_ui | D009942 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | administration & dosage |
| mesh[6].descriptor_name | Organometallic Compounds |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D017207 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Rats, Sprague-Dawley |
| mesh[8].qualifier_ui | Q000379 |
| mesh[8].descriptor_ui | D008279 |
| mesh[8].is_major_topic | True |
| mesh[8].qualifier_name | methods |
| mesh[8].descriptor_name | Magnetic Resonance Imaging |
| mesh[9].qualifier_ui | Q000493 |
| mesh[9].descriptor_ui | D006571 |
| mesh[9].is_major_topic | True |
| mesh[9].qualifier_name | pharmacokinetics |
| mesh[9].descriptor_name | Heterocyclic Compounds |
| mesh[10].qualifier_ui | Q000008 |
| mesh[10].descriptor_ui | D006571 |
| mesh[10].is_major_topic | True |
| mesh[10].qualifier_name | administration & dosage |
| mesh[10].descriptor_name | Heterocyclic Compounds |
| mesh[11].qualifier_ui | Q000493 |
| mesh[11].descriptor_ui | D005682 |
| mesh[11].is_major_topic | True |
| mesh[11].qualifier_name | pharmacokinetics |
| mesh[11].descriptor_name | Gadolinium |
| mesh[12].qualifier_ui | Q000008 |
| mesh[12].descriptor_ui | D005682 |
| mesh[12].is_major_topic | True |
| mesh[12].qualifier_name | administration & dosage |
| mesh[12].descriptor_name | Gadolinium |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D014018 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Tissue Distribution |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D006801 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Humans |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D004305 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Dose-Response Relationship, Drug |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D000818 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Animals |
| mesh[17].qualifier_ui | Q000493 |
| mesh[17].descriptor_ui | D003287 |
| mesh[17].is_major_topic | True |
| mesh[17].qualifier_name | pharmacokinetics |
| mesh[17].descriptor_name | Contrast Media |
| mesh[18].qualifier_ui | Q000008 |
| mesh[18].descriptor_ui | D003287 |
| mesh[18].is_major_topic | True |
| mesh[18].qualifier_name | administration & dosage |
| mesh[18].descriptor_name | Contrast Media |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D051381 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Rats |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D005260 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Female |
| mesh[21].qualifier_ui | Q000493 |
| mesh[21].descriptor_ui | D009942 |
| mesh[21].is_major_topic | True |
| mesh[21].qualifier_name | pharmacokinetics |
| mesh[21].descriptor_name | Organometallic Compounds |
| mesh[22].qualifier_ui | Q000008 |
| mesh[22].descriptor_ui | D009942 |
| mesh[22].is_major_topic | True |
| mesh[22].qualifier_name | administration & dosage |
| mesh[22].descriptor_name | Organometallic Compounds |
| mesh[23].qualifier_ui | |
| mesh[23].descriptor_ui | D017207 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | |
| mesh[23].descriptor_name | Rats, Sprague-Dawley |
| mesh[24].qualifier_ui | Q000379 |
| mesh[24].descriptor_ui | D008279 |
| mesh[24].is_major_topic | True |
| mesh[24].qualifier_name | methods |
| mesh[24].descriptor_name | Magnetic Resonance Imaging |
| mesh[25].qualifier_ui | Q000493 |
| mesh[25].descriptor_ui | D006571 |
| mesh[25].is_major_topic | True |
| mesh[25].qualifier_name | pharmacokinetics |
| mesh[25].descriptor_name | Heterocyclic Compounds |
| mesh[26].qualifier_ui | Q000008 |
| mesh[26].descriptor_ui | D006571 |
| mesh[26].is_major_topic | True |
| mesh[26].qualifier_name | administration & dosage |
| mesh[26].descriptor_name | Heterocyclic Compounds |
| mesh[27].qualifier_ui | Q000493 |
| mesh[27].descriptor_ui | D005682 |
| mesh[27].is_major_topic | True |
| mesh[27].qualifier_name | pharmacokinetics |
| mesh[27].descriptor_name | Gadolinium |
| mesh[28].qualifier_ui | Q000008 |
| mesh[28].descriptor_ui | D005682 |
| mesh[28].is_major_topic | True |
| mesh[28].qualifier_name | administration & dosage |
| mesh[28].descriptor_name | Gadolinium |
| mesh[29].qualifier_ui | |
| mesh[29].descriptor_ui | D014018 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | |
| mesh[29].descriptor_name | Tissue Distribution |
| mesh[30].qualifier_ui | |
| mesh[30].descriptor_ui | D006801 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | |
| mesh[30].descriptor_name | Humans |
| mesh[31].qualifier_ui | |
| mesh[31].descriptor_ui | D004305 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | |
| mesh[31].descriptor_name | Dose-Response Relationship, Drug |
| type | article |
| title | Overall Gadolinium Exposure Within the First 5 Months After Injection of Human Equivalent Doses of Gadopiclenol, Gadoterate, or Gadobutrol in Healthy Rats |
| biblio.issue | 11 |
| biblio.volume | 60 |
| biblio.last_page | 767 |
| biblio.first_page | 753 |
| topics[0].id | https://openalex.org/T11279 |
| topics[0].field.id | https://openalex.org/fields/25 |
| topics[0].field.display_name | Materials Science |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/3 |
| topics[0].domain.display_name | Physical Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2505 |
| topics[0].subfield.display_name | Materials Chemistry |
| topics[0].display_name | Lanthanide and Transition Metal Complexes |
| topics[1].id | https://openalex.org/T10378 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9998999834060669 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2741 |
| topics[1].subfield.display_name | Radiology, Nuclear Medicine and Imaging |
| topics[1].display_name | Advanced MRI Techniques and Applications |
| topics[2].id | https://openalex.org/T10522 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9995999932289124 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2741 |
| topics[2].subfield.display_name | Radiology, Nuclear Medicine and Imaging |
| topics[2].display_name | Medical Imaging Techniques and Applications |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2776875665 |
| concepts[0].level | 3 |
| concepts[0].score | 0.8555020093917847 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q2570844 |
| concepts[0].display_name | Gadobutrol |
| concepts[1].id | https://openalex.org/C557651011 |
| concepts[1].level | 2 |
| concepts[1].score | 0.8464645743370056 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q1832 |
| concepts[1].display_name | Gadolinium |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.650979220867157 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C2989005 |
| concepts[3].level | 1 |
| concepts[3].score | 0.4823174476623535 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q214963 |
| concepts[3].display_name | Nuclear medicine |
| concepts[4].id | https://openalex.org/C147583825 |
| concepts[4].level | 2 |
| concepts[4].score | 0.44235819578170776 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q620876 |
| concepts[4].display_name | Body weight |
| concepts[5].id | https://openalex.org/C143409427 |
| concepts[5].level | 2 |
| concepts[5].score | 0.2945254147052765 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q161238 |
| concepts[5].display_name | Magnetic resonance imaging |
| concepts[6].id | https://openalex.org/C126322002 |
| concepts[6].level | 1 |
| concepts[6].score | 0.2928774356842041 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[6].display_name | Internal medicine |
| concepts[7].id | https://openalex.org/C185592680 |
| concepts[7].level | 0 |
| concepts[7].score | 0.24044790863990784 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[7].display_name | Chemistry |
| concepts[8].id | https://openalex.org/C126838900 |
| concepts[8].level | 1 |
| concepts[8].score | 0.18320971727371216 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q77604 |
| concepts[8].display_name | Radiology |
| concepts[9].id | https://openalex.org/C178790620 |
| concepts[9].level | 1 |
| concepts[9].score | 0.0 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q11351 |
| concepts[9].display_name | Organic chemistry |
| keywords[0].id | https://openalex.org/keywords/gadobutrol |
| keywords[0].score | 0.8555020093917847 |
| keywords[0].display_name | Gadobutrol |
| keywords[1].id | https://openalex.org/keywords/gadolinium |
| keywords[1].score | 0.8464645743370056 |
| keywords[1].display_name | Gadolinium |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.650979220867157 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/nuclear-medicine |
| keywords[3].score | 0.4823174476623535 |
| keywords[3].display_name | Nuclear medicine |
| keywords[4].id | https://openalex.org/keywords/body-weight |
| keywords[4].score | 0.44235819578170776 |
| keywords[4].display_name | Body weight |
| keywords[5].id | https://openalex.org/keywords/magnetic-resonance-imaging |
| keywords[5].score | 0.2945254147052765 |
| keywords[5].display_name | Magnetic resonance imaging |
| keywords[6].id | https://openalex.org/keywords/internal-medicine |
| keywords[6].score | 0.2928774356842041 |
| keywords[6].display_name | Internal medicine |
| keywords[7].id | https://openalex.org/keywords/chemistry |
| keywords[7].score | 0.24044790863990784 |
| keywords[7].display_name | Chemistry |
| keywords[8].id | https://openalex.org/keywords/radiology |
| keywords[8].score | 0.18320971727371216 |
| keywords[8].display_name | Radiology |
| language | en |
| locations[0].id | doi:10.1097/rli.0000000000001194 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S136338150 |
| locations[0].source.issn | 0020-9996, 1536-0210 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0020-9996 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Investigative Radiology |
| locations[0].source.host_organization | https://openalex.org/P4310315671 |
| locations[0].source.host_organization_name | Lippincott Williams & Wilkins |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310315671, https://openalex.org/P4310318547 |
| locations[0].source.host_organization_lineage_names | Lippincott Williams & Wilkins, Wolters Kluwer |
| locations[0].license | cc-by-nc-nd |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc-nd |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Investigative Radiology |
| locations[0].landing_page_url | https://doi.org/10.1097/rli.0000000000001194 |
| locations[1].id | pmid:40384088 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Investigative radiology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40384088 |
| locations[2].id | pmh:oai:europepmc.org:11300880 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306400806 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | Europe PMC (PubMed Central) |
| locations[2].source.host_organization | https://openalex.org/I1303153112 |
| locations[2].source.host_organization_name | European Bioinformatics Institute |
| locations[2].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/12490341 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5055781740 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-6930-6858 |
| authorships[0].author.display_name | Marlène Rasschaert |
| authorships[0].countries | FR |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I120615911 |
| authorships[0].affiliations[0].raw_affiliation_string | From the Guerbet, Research and Innovation Department, Aulnay-sous-Bois, France. |
| authorships[0].institutions[0].id | https://openalex.org/I120615911 |
| authorships[0].institutions[0].ror | https://ror.org/0504sxa76 |
| authorships[0].institutions[0].type | company |
| authorships[0].institutions[0].lineage | https://openalex.org/I120615911 |
| authorships[0].institutions[0].country_code | FR |
| authorships[0].institutions[0].display_name | Guerbet (France) |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Marlène Rasschaert |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | From the Guerbet, Research and Innovation Department, Aulnay-sous-Bois, France. |
| authorships[1].author.id | https://openalex.org/A5093224409 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Emilie Couloumy |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Emilie Couloumy |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5117469586 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Elisabeth Renard |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Elisabeth Renard |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5114102072 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Claire Hollenbeck |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Claire Hollenbeck |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5048991357 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-4551-422X |
| authorships[4].author.display_name | Nathalie Fretellier |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Nathalie Fretellier |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5021273003 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Izabela Strzeminska |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Izabela Strzeminska |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5117601074 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Ilona Janot |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Ilona Janot |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5061390498 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-4307-2157 |
| authorships[7].author.display_name | Margeaux Lefebvre |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Mylene Lefebvre |
| authorships[7].is_corresponding | False |
| authorships[8].author.id | https://openalex.org/A5107820174 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | Nathalie Decout |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Nathalie Decout |
| authorships[8].is_corresponding | False |
| authorships[9].author.id | https://openalex.org/A5065874712 |
| authorships[9].author.orcid | https://orcid.org/0000-0003-0904-8716 |
| authorships[9].author.display_name | Cécile Factor |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Cecile Factor |
| authorships[9].is_corresponding | False |
| authorships[10].author.id | https://openalex.org/A5085134628 |
| authorships[10].author.orcid | https://orcid.org/0000-0001-8744-7363 |
| authorships[10].author.display_name | Philippe Robert |
| authorships[10].author_position | last |
| authorships[10].raw_author_name | Philippe Robert |
| authorships[10].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1097/rli.0000000000001194 |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Overall Gadolinium Exposure Within the First 5 Months After Injection of Human Equivalent Doses of Gadopiclenol, Gadoterate, or Gadobutrol in Healthy Rats |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11279 |
| primary_topic.field.id | https://openalex.org/fields/25 |
| primary_topic.field.display_name | Materials Science |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/3 |
| primary_topic.domain.display_name | Physical Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2505 |
| primary_topic.subfield.display_name | Materials Chemistry |
| primary_topic.display_name | Lanthanide and Transition Metal Complexes |
| related_works | https://openalex.org/W4301391107, https://openalex.org/W4283259974, https://openalex.org/W2803232995, https://openalex.org/W3011727973, https://openalex.org/W2094149890, https://openalex.org/W4297855528, https://openalex.org/W2035316823, https://openalex.org/W3002091697, https://openalex.org/W2901235313, https://openalex.org/W2955410492 |
| cited_by_count | 0 |
| locations_count | 3 |
| best_oa_location.id | doi:10.1097/rli.0000000000001194 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S136338150 |
| best_oa_location.source.issn | 0020-9996, 1536-0210 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0020-9996 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Investigative Radiology |
| best_oa_location.source.host_organization | https://openalex.org/P4310315671 |
| best_oa_location.source.host_organization_name | Lippincott Williams & Wilkins |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310315671, https://openalex.org/P4310318547 |
| best_oa_location.source.host_organization_lineage_names | Lippincott Williams & Wilkins, Wolters Kluwer |
| best_oa_location.license | cc-by-nc-nd |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Investigative Radiology |
| best_oa_location.landing_page_url | https://doi.org/10.1097/rli.0000000000001194 |
| primary_location.id | doi:10.1097/rli.0000000000001194 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S136338150 |
| primary_location.source.issn | 0020-9996, 1536-0210 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0020-9996 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Investigative Radiology |
| primary_location.source.host_organization | https://openalex.org/P4310315671 |
| primary_location.source.host_organization_name | Lippincott Williams & Wilkins |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310315671, https://openalex.org/P4310318547 |
| primary_location.source.host_organization_lineage_names | Lippincott Williams & Wilkins, Wolters Kluwer |
| primary_location.license | cc-by-nc-nd |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Investigative Radiology |
| primary_location.landing_page_url | https://doi.org/10.1097/rli.0000000000001194 |
| publication_date | 2025-05-19 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W2150489367, https://openalex.org/W2125409822, https://openalex.org/W2983525439, https://openalex.org/W3212095163, https://openalex.org/W3039030012, https://openalex.org/W4367857438, https://openalex.org/W4390919543, https://openalex.org/W2931677153, https://openalex.org/W4403209514, https://openalex.org/W2982408692, https://openalex.org/W4388288267, https://openalex.org/W4396667611, https://openalex.org/W2999830370, https://openalex.org/W4318935406, https://openalex.org/W4384627378, https://openalex.org/W4387439830, https://openalex.org/W4401690696, https://openalex.org/W4406751062, https://openalex.org/W3167478299, https://openalex.org/W4226103678, https://openalex.org/W4283259974, https://openalex.org/W4388302622, https://openalex.org/W2921998404, https://openalex.org/W3129079275, https://openalex.org/W4225363049, https://openalex.org/W4220652826, https://openalex.org/W4385632186, https://openalex.org/W4404582623, https://openalex.org/W2077972765, https://openalex.org/W2327310966, https://openalex.org/W4248740079, https://openalex.org/W3070754678, https://openalex.org/W4394611450, https://openalex.org/W4400527842, https://openalex.org/W4296033954, https://openalex.org/W2515055839, https://openalex.org/W2353345075, https://openalex.org/W4392767713, https://openalex.org/W4387425903, https://openalex.org/W3191672603, https://openalex.org/W2329419847, https://openalex.org/W2763313954, https://openalex.org/W2799589193, https://openalex.org/W2108281282, https://openalex.org/W2159120715, https://openalex.org/W2171037005, https://openalex.org/W1977759660, https://openalex.org/W2062377319, https://openalex.org/W2018924991, https://openalex.org/W2801750152 |
| referenced_works_count | 50 |
| abstract_inverted_index.% | 406 |
| abstract_inverted_index.1 | 156, 180, 183, 186 |
| abstract_inverted_index.2 | 121 |
| abstract_inverted_index.4 | 153 |
| abstract_inverted_index.5 | 190, 239, 288, 422 |
| abstract_inverted_index.= | 197 |
| abstract_inverted_index.a | 3, 104, 113, 272 |
| abstract_inverted_index.(n | 196 |
| abstract_inverted_index.10 | 397, 401 |
| abstract_inverted_index.Gd | 80, 101, 220, 230, 244, 285, 307, 348, 379, 419 |
| abstract_inverted_index.In | 97, 344 |
| abstract_inverted_index.at | 49, 86, 134, 233, 281, 429 |
| abstract_inverted_index.be | 293 |
| abstract_inverted_index.by | 25, 35, 250, 305 |
| abstract_inverted_index.in | 22, 32, 76, 109, 118, 245, 271, 316, 362, 374, 381, 427 |
| abstract_inverted_index.is | 2, 46, 91, 310, 385, 432 |
| abstract_inverted_index.of | 70, 78, 116, 160, 366, 409 |
| abstract_inverted_index.on | 229 |
| abstract_inverted_index.or | 173, 189, 355 |
| abstract_inverted_index.to | 57, 66, 152, 243, 279, 292, 295, 299, 358, 389, 400 |
| abstract_inverted_index.0.3 | 171 |
| abstract_inverted_index.0.6 | 163, 167 |
| abstract_inverted_index.25% | 294 |
| abstract_inverted_index.40% | 296 |
| abstract_inverted_index.CNS | 319 |
| abstract_inverted_index.HED | 431 |
| abstract_inverted_index.PNS | 329 |
| abstract_inverted_index.The | 266 |
| abstract_inverted_index.all | 132 |
| abstract_inverted_index.and | 7, 18, 28, 31, 40, 130, 142, 199, 206, 261, 301, 341, 360, 370, 439 |
| abstract_inverted_index.but | 372 |
| abstract_inverted_index.day | 181 |
| abstract_inverted_index.for | 13, 126, 217 |
| abstract_inverted_index.low | 387 |
| abstract_inverted_index.our | 413 |
| abstract_inverted_index.the | 26, 36, 58, 68, 100, 194, 238, 252, 255, 259, 262, 282, 313, 317, 335, 337, 339, 342, 345, 347, 363, 367, 375, 390, 416, 430 |
| abstract_inverted_index.was | 107, 248, 269, 290, 353 |
| abstract_inverted_index.(Gd) | 73 |
| abstract_inverted_index.(M5) | 192 |
| abstract_inverted_index.2022 | 24 |
| abstract_inverted_index.2023 | 34 |
| abstract_inverted_index.Body | 19 |
| abstract_inverted_index.Drug | 29 |
| abstract_inverted_index.Food | 27 |
| abstract_inverted_index.HED, | 283 |
| abstract_inverted_index.MRI, | 20 |
| abstract_inverted_index.This | 63 |
| abstract_inverted_index.aims | 65 |
| abstract_inverted_index.area | 253 |
| abstract_inverted_index.body | 54, 81 |
| abstract_inverted_index.bone | 368, 376 |
| abstract_inverted_index.dose | 74, 139 |
| abstract_inverted_index.each | 246, 382 |
| abstract_inverted_index.from | 396 |
| abstract_inverted_index.half | 50 |
| abstract_inverted_index.high | 4 |
| abstract_inverted_index.last | 263 |
| abstract_inverted_index.mass | 226 |
| abstract_inverted_index.only | 92 |
| abstract_inverted_index.over | 103, 287, 312, 421 |
| abstract_inverted_index.rats | 111, 148, 280, 428 |
| abstract_inverted_index.than | 435 |
| abstract_inverted_index.that | 436 |
| abstract_inverted_index.this | 71, 89, 98 |
| abstract_inverted_index.time | 236, 264 |
| abstract_inverted_index.use, | 128 |
| abstract_inverted_index.week | 184 |
| abstract_inverted_index.were | 149, 178, 215 |
| abstract_inverted_index.with | 120, 222, 393 |
| abstract_inverted_index.−3 | 402 |
| abstract_inverted_index.−6 | 398 |
| abstract_inverted_index.(0.05 | 52 |
| abstract_inverted_index.(CNS) | 17, 399 |
| abstract_inverted_index.(D1), | 182 |
| abstract_inverted_index.(M1), | 188 |
| abstract_inverted_index.(W1), | 185 |
| abstract_inverted_index.Agent | 11 |
| abstract_inverted_index.Based | 228 |
| abstract_inverted_index.GBCAs | 124 |
| abstract_inverted_index.Organ | 304 |
| abstract_inverted_index.Under | 412 |
| abstract_inverted_index.[CNS] | 205 |
| abstract_inverted_index.[PNS] | 210 |
| abstract_inverted_index.after | 112, 193, 350, 437 |
| abstract_inverted_index.bone) | 214, 405 |
| abstract_inverted_index.brain | 325 |
| abstract_inverted_index.curve | 256 |
| abstract_inverted_index.first | 260 |
| abstract_inverted_index.found | 291, 380 |
| abstract_inverted_index.human | 127, 137 |
| abstract_inverted_index.lower | 297, 373, 434 |
| abstract_inverted_index.month | 187 |
| abstract_inverted_index.organ | 247 |
| abstract_inverted_index.other | 59, 122 |
| abstract_inverted_index.parts | 365 |
| abstract_inverted_index.skin, | 338 |
| abstract_inverted_index.stem, | 326 |
| abstract_inverted_index.study | 64, 268 |
| abstract_inverted_index.terms | 77 |
| abstract_inverted_index.their | 135 |
| abstract_inverted_index.these | 234 |
| abstract_inverted_index.total | 219 |
| abstract_inverted_index.under | 254 |
| abstract_inverted_index.whole | 267 |
| abstract_inverted_index.(AUC), | 257 |
| abstract_inverted_index.(GBCA) | 12 |
| abstract_inverted_index.(HED). | 140 |
| abstract_inverted_index.Agency | 39 |
| abstract_inverted_index.GBCAs. | 62 |
| abstract_inverted_index.animal | 95 |
| abstract_inverted_index.brain, | 322, 324 |
| abstract_inverted_index.cord), | 328 |
| abstract_inverted_index.dose), | 392 |
| abstract_inverted_index.dose/g | 408 |
| abstract_inverted_index.female | 146 |
| abstract_inverted_index.femur, | 346 |
| abstract_inverted_index.health | 43 |
| abstract_inverted_index.higher | 354 |
| abstract_inverted_index.impact | 69 |
| abstract_inverted_index.liver, | 340 |
| abstract_inverted_index.months | 191, 240, 289, 423 |
| abstract_inverted_index.nerve, | 333 |
| abstract_inverted_index.nodes, | 331 |
| abstract_inverted_index.organ, | 306 |
| abstract_inverted_index.organ. | 410 |
| abstract_inverted_index.others | 41 |
| abstract_inverted_index.period | 106, 315 |
| abstract_inverted_index.plasma | 225 |
| abstract_inverted_index.point. | 265 |
| abstract_inverted_index.saline | 174 |
| abstract_inverted_index.single | 114, 157 |
| abstract_inverted_index.spinal | 327 |
| abstract_inverted_index.study, | 99 |
| abstract_inverted_index.system | 16, 209 |
| abstract_inverted_index.times, | 88 |
| abstract_inverted_index.tissue | 84, 383 |
| abstract_inverted_index.values | 394 |
| abstract_inverted_index.(spinal | 330 |
| abstract_inverted_index.5-month | 105 |
| abstract_inverted_index.Animals | 177 |
| abstract_inverted_index.Healthy | 144 |
| abstract_inverted_index.between | 258 |
| abstract_inverted_index.blinded | 273 |
| abstract_inverted_index.central | 14, 204 |
| abstract_inverted_index.coupled | 224 |
| abstract_inverted_index.group). | 176 |
| abstract_inverted_index.groups, | 154 |
| abstract_inverted_index.healthy | 110 |
| abstract_inverted_index.kidney. | 343 |
| abstract_inverted_index.manner. | 274 |
| abstract_inverted_index.marrow. | 377 |
| abstract_inverted_index.mineral | 364, 404 |
| abstract_inverted_index.mmol/kg | 53 |
| abstract_inverted_index.nervous | 15, 208 |
| abstract_inverted_index.organs, | 211, 213 |
| abstract_inverted_index.overall | 79, 241, 284, 417 |
| abstract_inverted_index.plasma, | 318 |
| abstract_inverted_index.points, | 237 |
| abstract_inverted_index.ranging | 395 |
| abstract_inverted_index.samples | 85 |
| abstract_inverted_index.sciatic | 332 |
| abstract_inverted_index.spleen, | 336 |
| abstract_inverted_index.studied | 314, 384 |
| abstract_inverted_index.through | 94 |
| abstract_inverted_index.tissues | 202 |
| abstract_inverted_index.weight) | 55 |
| abstract_inverted_index.(control | 175 |
| abstract_inverted_index.(kidney, | 403 |
| abstract_inverted_index.10/group | 198 |
| abstract_inverted_index.25–40% | 433 |
| abstract_inverted_index.Contrast | 10 |
| abstract_inverted_index.December | 33 |
| abstract_inverted_index.European | 37, 42 |
| abstract_inverted_index.Material | 141 |
| abstract_inverted_index.Medicine | 38 |
| abstract_inverted_index.Methods: | 143 |
| abstract_inverted_index.Residual | 378 |
| abstract_inverted_index.Results: | 275 |
| abstract_inverted_index.Selected | 201 |
| abstract_inverted_index.approved | 21, 125 |
| abstract_inverted_index.compared | 56, 298, 357 |
| abstract_inverted_index.cortical | 321 |
| abstract_inverted_index.evaluate | 67 |
| abstract_inverted_index.exposure | 102, 242, 286, 308, 349, 420 |
| abstract_inverted_index.injected | 391, 407 |
| abstract_inverted_index.marketed | 61 |
| abstract_inverted_index.measured | 418 |
| abstract_inverted_index.nonionic | 8 |
| abstract_inverted_index.observed | 311 |
| abstract_inverted_index.randomly | 150 |
| abstract_inverted_index.relative | 388 |
| abstract_inverted_index.(Dotarem, | 162 |
| abstract_inverted_index.Following | 276 |
| abstract_inverted_index.Requiring | 83 |
| abstract_inverted_index.September | 23 |
| abstract_inverted_index.allocated | 151 |
| abstract_inverted_index.collected | 216 |
| abstract_inverted_index.currently | 47 |
| abstract_inverted_index.different | 87, 235 |
| abstract_inverted_index.estimated | 249 |
| abstract_inverted_index.evaluated | 108 |
| abstract_inverted_index.excretion | 212 |
| abstract_inverted_index.exposure. | 82 |
| abstract_inverted_index.extremely | 386 |
| abstract_inverted_index.following | 424 |
| abstract_inverted_index.indicated | 48 |
| abstract_inverted_index.injection | 115, 159, 195, 426 |
| abstract_inverted_index.mmol/kg), | 164, 168, 172 |
| abstract_inverted_index.performed | 270 |
| abstract_inverted_index.receiving | 155 |
| abstract_inverted_index.reduction | 75, 309 |
| abstract_inverted_index.(Elucirem, | 170 |
| abstract_inverted_index.(Gadovist, | 166 |
| abstract_inverted_index.(diaphysis | 369 |
| abstract_inverted_index.(including | 203 |
| abstract_inverted_index.9-week-old | 145 |
| abstract_inverted_index.accessible | 93 |
| abstract_inverted_index.comparison | 119 |
| abstract_inverted_index.equivalent | 138, 356 |
| abstract_inverted_index.euthanized | 179 |
| abstract_inverted_index.footpads), | 334 |
| abstract_inverted_index.gadobutrol | 129, 165, 359, 440 |
| abstract_inverted_index.gadolinium | 72 |
| abstract_inverted_index.gadoterate | 161, 300, 361, 438 |
| abstract_inverted_index.peripheric | 207 |
| abstract_inverted_index.relaxivity | 5 |
| abstract_inverted_index.respective | 136 |
| abstract_inverted_index.subsequent | 218 |
| abstract_inverted_index.calculating | 251 |
| abstract_inverted_index.conditions, | 415 |
| abstract_inverted_index.epiphysis), | 371 |
| abstract_inverted_index.experiment. | 96 |
| abstract_inverted_index.gadobutrol, | 302 |
| abstract_inverted_index.gadoterate, | 131 |
| abstract_inverted_index.inductively | 223 |
| abstract_inverted_index.information | 90 |
| abstract_inverted_index.injections, | 441 |
| abstract_inverted_index.intravenous | 158 |
| abstract_inverted_index.macrocyclic | 6, 123 |
| abstract_inverted_index.nonspecific | 60 |
| abstract_inverted_index.subcortical | 323 |
| abstract_inverted_index.(cerebellum, | 320 |
| abstract_inverted_index.Conclusions: | 411 |
| abstract_inverted_index.Gadopiclenol | 1, 45 |
| abstract_inverted_index.administered | 133 |
| abstract_inverted_index.authorities. | 44 |
| abstract_inverted_index.experimental | 414 |
| abstract_inverted_index.gadopiclenol | 117, 169, 277, 351, 425 |
| abstract_inverted_index.measurements | 232 |
| abstract_inverted_index.time-point). | 200 |
| abstract_inverted_index.Introduction: | 0 |
| abstract_inverted_index.concentration | 231 |
| abstract_inverted_index.determination | 221 |
| abstract_inverted_index.respectively. | 303, 442 |
| abstract_inverted_index.spectrometry. | 227 |
| abstract_inverted_index.Administration | 30 |
| abstract_inverted_index.Sprague-Dawley | 147 |
| abstract_inverted_index.administration | 278, 352 |
| abstract_inverted_index.gadolinium-dose | 51 |
| abstract_inverted_index.Gadolinium-Based | 9 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 11 |
| citation_normalized_percentile.value | 0.15811103 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |